Hemogenyx Pharmaceuticals plc (LSE:HEMO) is thrilled to report the successful accomplishment of its second Process Qualification (“PQ”) run of the end-to-end manufacturing process for its pioneering HEMO-CAR-T cells in its cGMP compliant clean rooms. Subsequently, a comprehensive set of analytical release tests were conducted to ensure the highest quality of the manufactured HEMO-CAR-T cells.
This PQ run is the second of three identical manufacturing runs required to submit an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for authorization to commence Phase I clinical trials of HEMO-CAR-T. With this milestone, we are one step closer to potentially revolutionizing the treatment of cancer patients.
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals, a publicly traded company listed on the London Stock Exchange (LSE: HEMO), is a revolutionary biotechnology company based in the UK and USA. Its US subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, are located in New York City at a cutting-edge research facility. The company is dedicated to discovering and developing breakthrough therapies and treatments to improve health, extend life, and ultimately make the world a better place.
Hemogenyx Pharmaceuticals is a pre-clinical stage biopharmaceutical group that is revolutionizing the way we treat life-threatening blood and autoimmune diseases. With their cutting-edge treatments and medicines, they seek to bring the curative power of bone marrow transplantation to many more patients in need. In addition, their innovative platform technologies are being used as engines to develop novel products, giving them the potential to make a huge impact on the healthcare industry.
Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange, provides vital information to keep you up to date. Be sure to review the terms and conditions that apply to the use and distribution of this information.